Withania somnifera extracts induced attenuation of HIV-1: a mechanistic approach to restrict viral infection.
Anti-HIV-1
Ashwagandha
Ashwagandhanolide
Molecular docking
Withacoagin
Withaferin
Withania somnifera
Withanolide
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
03 08 2023
03 08 2023
Historique:
received:
07
04
2023
accepted:
15
07
2023
medline:
7
8
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Several anti-retroviral drugs are available against Human immunodeficiency virus type-1, but have multiple adverse side effects. Hence, there is an incessant compulsion for effectual anti-retroviral agents with minimal or no intricacy. Traditionally, natural products have been the most successful source for the development of new medications. Withania somnifera, also known as Ashwagandha, is the utmost treasured medicinal plant used in Ayurveda, which holds the potential to give adaptogenic, immunomodulatory, and antiviral effects. However, its effect on HIV-1 replication at the cellular level has never been explored. Herein, we focused on the anti-HIV-1 activity and the probable mechanism of action of hydroalcoholic and aqueous extracts of Withania somnifera roots and its phytomolecules. The cytotoxicity of the extracts was determined through MTT assay, while the in vitro anti-HIV-1 activity was assessed in TZM-bl cells against the HIV-1 strains of X4 and R5 subtypes. Results were confirmed in peripheral blood mononuclear cells, using the HIV-1 p24 antigen assay. Additionally, the mechanism of action was determined through the Time of Addition assay, which was further validated through the series of enzymatic assays, i.e. HIV-1 Integrase, Reverse transcriptase, and Protease assays. To explore the role of the identified active metabolites of Withania somnifera in antiretroviral activity, molecular docking analyses were performed against these key HIV-1 replication enzymes. The hydroalcoholic and aqueous extracts of Withania somnifera roots were found to be safer at the sub-cytotoxic concentrations and exhibited their ability to inhibit replication of two primary isolates of HIV-1 through cell-associated and cell-free assays, in dose-dependent kinetics. Several active phytomolecules found in Withania somnifera successfully established hydrogens bonds in the active binding pocket site residues responsible for the catalytic activity of HIV replication and therefore, signifying their role in the attenuation of HIV-1 infection as implied through the in silico molecular docking studies. Our research identified both the hydroalcoholic and aqueous extracts of Withania somnifera roots as potent inhibitors of HIV-1 infection. The in silico analyses also indicated the key components of Withania somnifera with the highest binding affinity against the HIV-1 Integrase by 12-Deoxywithastramonolide and 27-Hydroxywithanone, HIV-1 Protease by Ashwagandhanolide and Withacoagin, and HIV-1 Reverse transcriptase by Ashwagandhanolide and Withanolide B, thereby showing possible mechanisms of HIV-1 extenuation. Overall, this study classified the role of Withania somnifera extracts and their active compounds as potential agents against HIV-1 infection.
Sections du résumé
BACKGROUND
Several anti-retroviral drugs are available against Human immunodeficiency virus type-1, but have multiple adverse side effects. Hence, there is an incessant compulsion for effectual anti-retroviral agents with minimal or no intricacy. Traditionally, natural products have been the most successful source for the development of new medications. Withania somnifera, also known as Ashwagandha, is the utmost treasured medicinal plant used in Ayurveda, which holds the potential to give adaptogenic, immunomodulatory, and antiviral effects. However, its effect on HIV-1 replication at the cellular level has never been explored. Herein, we focused on the anti-HIV-1 activity and the probable mechanism of action of hydroalcoholic and aqueous extracts of Withania somnifera roots and its phytomolecules.
METHODS
The cytotoxicity of the extracts was determined through MTT assay, while the in vitro anti-HIV-1 activity was assessed in TZM-bl cells against the HIV-1 strains of X4 and R5 subtypes. Results were confirmed in peripheral blood mononuclear cells, using the HIV-1 p24 antigen assay. Additionally, the mechanism of action was determined through the Time of Addition assay, which was further validated through the series of enzymatic assays, i.e. HIV-1 Integrase, Reverse transcriptase, and Protease assays. To explore the role of the identified active metabolites of Withania somnifera in antiretroviral activity, molecular docking analyses were performed against these key HIV-1 replication enzymes.
RESULTS
The hydroalcoholic and aqueous extracts of Withania somnifera roots were found to be safer at the sub-cytotoxic concentrations and exhibited their ability to inhibit replication of two primary isolates of HIV-1 through cell-associated and cell-free assays, in dose-dependent kinetics. Several active phytomolecules found in Withania somnifera successfully established hydrogens bonds in the active binding pocket site residues responsible for the catalytic activity of HIV replication and therefore, signifying their role in the attenuation of HIV-1 infection as implied through the in silico molecular docking studies.
CONCLUSIONS
Our research identified both the hydroalcoholic and aqueous extracts of Withania somnifera roots as potent inhibitors of HIV-1 infection. The in silico analyses also indicated the key components of Withania somnifera with the highest binding affinity against the HIV-1 Integrase by 12-Deoxywithastramonolide and 27-Hydroxywithanone, HIV-1 Protease by Ashwagandhanolide and Withacoagin, and HIV-1 Reverse transcriptase by Ashwagandhanolide and Withanolide B, thereby showing possible mechanisms of HIV-1 extenuation. Overall, this study classified the role of Withania somnifera extracts and their active compounds as potential agents against HIV-1 infection.
Identifiants
pubmed: 37537596
doi: 10.1186/s12985-023-02130-y
pii: 10.1186/s12985-023-02130-y
pmc: PMC10401819
doi:
Substances chimiques
Plant Extracts
0
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
173Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
PLoS One. 2015 Sep 03;10(9):e0137498
pubmed: 26334881
Front Microbiol. 2016 Jan 12;6:1444
pubmed: 26793166
J Ethnopharmacol. 2020 Jun 12;255:112759
pubmed: 32173425
Rev Clin Esp (Barc). 2015 Nov;215(8):468-72
pubmed: 26298546
J Int AIDS Soc. 2012 Mar 16;15(1):16
pubmed: 22424402
Plants (Basel). 2021 Oct 07;10(10):
pubmed: 34685933
Molecules. 2009 Jul 03;14(7):2373-93
pubmed: 19633611
J Evid Based Integr Med. 2018 Jan-Dec;23:2156587218757661
pubmed: 29484895
Molecules. 2010 Apr 27;15(5):3048-78
pubmed: 20657464
Phytother Res. 2013 Aug;27(8):1169-78
pubmed: 22996349
Cell Biochem Biophys. 2015 Jul;72(3):727-39
pubmed: 25627548
Int J Mol Sci. 2009 May 20;10(5):2367-2382
pubmed: 19564954
Front Pharmacol. 2021 May 03;12:623795
pubmed: 34012390
Altern Med Rev. 2000 Aug;5(4):334-46
pubmed: 10956379
Int J Mol Sci. 2019 Oct 25;20(21):
pubmed: 31731424
J Clin Pharmacol. 2022 Jul;62(7):835-846
pubmed: 34990024
J Biomol Struct Dyn. 2022 Aug;40(12):5295-5308
pubmed: 33459174
J Nat Prod. 2012 Mar 23;75(3):311-35
pubmed: 22316239
Evid Based Complement Alternat Med. 2018 May 15;2018:2481076
pubmed: 29861767
Methods Mol Med. 1999;17:309-15
pubmed: 21380682
Phytother Res. 2009 Jul;23(7):987-92
pubmed: 19152372
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Drug Des Devel Ther. 2021 Mar 11;15:1111-1133
pubmed: 33737804
Oxid Med Cell Longev. 2016;2016:8910396
pubmed: 27829986
Indian J Exp Biol. 1997 Mar;35(3):236-9
pubmed: 9332168
Evid Based Complement Alternat Med. 2020 Jun 7;2020:9648056
pubmed: 32595755
Sci Rep. 2016 Feb 02;6:20394
pubmed: 26833261
Drug Discov Today. 2005 Apr 1;10(7):495-502
pubmed: 15809195
J Biomol Struct Dyn. 2021 Aug;39(12):4510-4521
pubmed: 32568012
BMC Complement Altern Med. 2011 Aug 19;11:65
pubmed: 21854608
Pharmaceuticals (Basel). 2021 Oct 31;14(11):
pubmed: 34832897
Virol Sin. 2021 Feb;36(1):141-144
pubmed: 32458296
BMC Bioinformatics. 2011;12 Suppl 13:S22
pubmed: 22373101
Pathog Dis. 2017 Aug 31;75(6):
pubmed: 28637198
PLoS One. 2021 Jun 11;16(6):e0248479
pubmed: 34115763
Evid Based Complement Alternat Med. 2011;2011:267614
pubmed: 20007262
Nat Protoc. 2011 Jun;6(6):925-33
pubmed: 21637207
Phytother Res. 1999 Jun;13(4):275-91
pubmed: 10404532
BMC Complement Med Ther. 2023 Mar 18;23(1):82
pubmed: 36934258
Antivir Ther. 2013;18(1):115-23
pubmed: 23052978
J Altern Complement Med. 2014 Dec;20(12):901-8
pubmed: 25405876
J Cheminform. 2012 Aug 13;4(1):17
pubmed: 22889332
Cells. 2019 Sep 27;8(10):
pubmed: 31569640
Vegetos. 2023;36(2):701-720
pubmed: 35729946
J Ayurveda Integr Med. 2012 Jul;3(3):111-4
pubmed: 23125505
Phytother Res. 2010 Jun;24(6):859-63
pubmed: 19957250
Antioxidants (Basel). 2022 Sep 28;11(10):
pubmed: 36290665
Indian J Exp Biol. 2010 Mar;48(3):220-7
pubmed: 21046974